All
Derms who 'give back' inspire colleagues
August 1st 2006In the past, I've used this space to rally for volunteerism/charitable endeavors and discuss outstanding services performed by those in dermatology. My sense has been that, while I'm not entirely "preaching to the choir," I am addressing a group of specialists, my fellow dermatologists, of whom many graciously give of their time in charitable medical and nonmedical ways.
Phase 3 infliximab psoriasis data positive at one year
July 29th 2006Results from one-year of follow-up in a phase 3 trial investigating infliximab (Remicade, Centocor) for the treatment of moderate to severe psoriasis demonstrate that the dramatic responses achieved rapidly after induction therapy are sustained with maintenance therapy in the majority of patients and without the emergence of new safety concerns, reported Alan Menter, M.D., at Academy '06.
Teledermatology revolutionizing rural care
July 29th 2006A network of teledermatology links throughout Alaska is providing cost-effective, timely access to dermatologic care for indigenous peoples in the nation's most underserved and sprawling state, its designer reports. Teledermatology programs organized by the Alaska Tribal Health System (ATHS) serve approximately 50,000 patients scattered throughout the state, reports John H. Bocachica, M.D., F.A.A.D., chief, dermatology and teledermatology at the Alaska Native Medical Center (ANMC) in Anchorage.
Dermatology antibiotic mainstays ineffective for community-acquired MRSA infections
July 28th 2006Dermatologists in outpatient practices should maintain an index of suspicion for infections caused by community-acquired methicillin resistant Staphylococcus aureus (CA-MRSA) and recognize the need to prescribe alternatives to the usual antibiotics that can be relied upon to effectively treat the majority of skin and skin structure infections they see, says Kenneth J. Tomecki, M.D., department of dermatology, The Cleveland Clinic Foundation.
Approval of HPV vaccine heralded for implications in preventing cervical cancer
July 28th 2006The very recent approval of the quadrivalent human papilloma virus (HPV) virus-like particle vaccine (Gardasil) is the biggest breakthrough in medicine in the 21st century so far because its prevents infection with the virus that is the second leading cause of cancer deaths in women worldwide, says Stephen K. Tyring, M.D., Ph.D.
Panniculitis - Reviewing the basics
July 28th 2006The most common cause of primary septal panniculitis is erythema nodosum. The clinical and microscopic features causing this disease are well known to the experienced dermatologist. The most common etiologic agents in erythema nodosum include infections (e.g. group A beta hemolytic strep, deep fungal and viral), drugs (e.g. oral contraceptives and sulfonamides), inflammatory bowel disease, sarcoidosis, pregnancy and malignancy.Dr. Robinson-Bostom says that, "We have found new associations concerning the etiologies in erythema nodosum. These include hepatitis C and HIV infections, all trans retinoic acid, echinacea herbal therapy, celiac disease, as well as carcinoid syndrome."
Take conservative approach to enjoy CO2 's plentiful benefits
July 1st 2006Scottsdale, Ariz. - Although it remains the gold standard for skin rejuvenation, CO2 laser resurfacing is paradoxically losing favor due to drawbacks ranging from the risk of complications to increasing patient reluctance over downtime and concerns about the complications.
Dermatologists struggle to meet patient demand
July 1st 2006National report - With demand for dermatologists' services outstripping supply in many areas of the country, sources say universities and other healthcare organizations are adding residency slots and pursuing innovative ideas to address patient access problems.
Self-regulation key in addressing industry conflicts of interest
July 1st 2006National report - Although the pharmaceutical industry and medical professional organizations have guidelines regarding physician relationships with industry, it is incumbent on individual professionals to apply those guidelines in such a way that they will maintain public trust and continue to serve their patients' best interests, says Stephen B. Webster, M.D., department of dermatology, Gundersen Lutheran Medical Center, La Crosse, Wis.
Langerhans cells dampen contact hypersensitivity
July 1st 2006New Haven, Conn. - Epidermal Langerhans cells (LCs), long thought to play a role in the initiation of contact hypersensitivity (CHS), appear to actually have quite the opposite function in the development of CHS responses, according to a report recently published in Immunity.
Safety standards evolving for nonhospital laser use
July 1st 2006Boston - Among the most important developments in safety standards that impact dermatology practices are changes involving laser use in non-hospital settings and development of international standards for intense pulsed light (IPL) devices, according to Penny J. Smalley, R.N., a Chicago-based safety consultant.
Studies demonstrate safety, efficacy of CaHA for facial lipoatrophy
July 1st 2006National report - Results of two parallel, prospective, open-label, North American studies demonstrate that treatment with the injectable filler consisting of microspheres of calcium hydroxylapatite (CaHA) in a carboxymethylcellulose gel carrier (Radiesse, BioForm Medical) provides safe, immediate and relatively durable restoration of facial volume in patients with HIV-associated lipoatrophy.